Semaglutide changed the conversation around obesity treatment faster than almost any drug in recent memory. However, the science hasn’t stood still since Ozempic and Wegovy became household names, and the next wave of compounds in development suggests the GLP-1 era is still in its early chapters. This piece looks at what semaglutide and tirzepatide have actually delivered, what’s coming next, and when patients might realistically expect access to it.
What GLP-1s Have Already Proven
Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) built their reputations on data, not hype. Tirzepatide’s dual GIP/GLP-1 mechanism has consistently outperformed single-mechanism GLP-1s in head-to-head weight loss comparisons, and both drugs have shown measurable benefits beyond the scale, including cardiovascular risk reduction, improved metabolic markers, and better outcomes for related conditions like sleep apnea and fatty liver disease. These aren’t marginal gains; they represent one of the more significant shifts in chronic disease management in decades.
Delivery format has also evolved. Oral tirzepatide drops and tablet formats have emerged as alternatives to injections for patients who want the same mechanism without the needle, a shift that matters for long-term adherence.
What’s Coming Next
The next generation of compounds isn’t just refining GLP-1; it’s expanding the target list entirely.
Retatrutide, Eli Lilly’s triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, has posted some of the strongest weight-loss numbers seen in a clinical trial to date.
In the TRIUMPH-1 Phase 3 trial, the highest dose produced an average of 28.3% weight loss, with 45.3% of participants achieving at least 30% weight loss, and a 104-week extension pushed that further with no plateau observed at 30.3% weight loss. That’s edging into territory previously associated only with bariatric surgery.
Beyond weight, retatrutide’s obstructive sleep apnea substudy showed a 60.6% reduction in the apnea-hypopnea index, exceeding tirzepatide’s own SURMOUNT-OSA results.
Orforglipron, marketed as Foundayo, took a different path, becoming the first non-peptide oral GLP-1 receptor agonist approved for obesity, receiving FDA approval on April 1, 2026. Unlike peptide-based oral options that require fasting and strict water timing, Foundayo can be taken at any time of day without food or water restrictions, a convenience difference that could meaningfully affect adherence. Its pivotal ATTAIN-1 trial showed a mean body weight reduction of 11.2% at the highest dose after 72 weeks, compared with 2.1% for placebo.
Amycretin, Novo Nordisk’s dual GLP-1/amylin candidate, has advanced to Phase 3 development following encouraging early-phase results, positioning amylin co-agonism as one of the more promising mechanisms still working through the pipeline.
Why This Matters Beyond the Headlines
Two things stand out across this new generation of compounds: oral formats are catching up to injectables in efficacy, and drugmakers are increasingly targeting multiple hormonal pathways at once rather than relying on GLP-1 alone.
Newer molecules represent metabolic therapies with applications reportedly extending toward brain health and renal disease, not just weight management, which suggests the category’s ceiling is still rising.
Staying Ahead of the Curve in Medically Supervised Weight Loss
As the GLP-1 landscape keeps expanding, patients increasingly need a provider that evolves alongside the science rather than sticking with a single formulation indefinitely.
Daytryp RX reflects that kind of forward-looking approach, offering both oral tirzepatide and semaglutide-based programs, including tirzepatide oral drops and semaglutide oral options, for patients who want the metabolic benefits of GLP-1 therapy without committing to an injection schedule.
With direct prescribing licenses in California and Arizona and a referral network reaching patients across 48 additional states, the platform is positioned to bring emerging treatment options to a wide base of patients as they clear regulatory approval.
Curious whether oral GLP-1 therapy is right for you? Get started with Daytryp RX to see if you’re eligible.
About the Author
This article was contributed by the team at Daytryp RX, a telehealth provider committed to expanding access to personalized mental health and wellness care. Through provider-guided ketamine therapy, medical weight management, hormone optimization, and ongoing clinical support, Daytryp RX helps eligible patients pursue meaningful improvements in their emotional and physical well-being through convenient virtual care.
